Abstract

Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.

Links

Publisher Full Text

Authors

Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ

Institution

Haematology Department, Hospital del Mar, Barcelona, Spain. asalar@hospitaldelmar.cat

Source

Leukemia research 36:5 2012 May pg 548-53

MeSH

Adult
Aged
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Doxorubicin
Female
Granulocyte Colony-Stimulating Factor
Humans
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Multivariate Analysis
Neutropenia
Prednisone
Risk Assessment
Risk Factors
Vincristine

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22385870